Upadacitinib and Warfarin Drug Interaction Resulting in Significantly Increased International Normalized Ratio: A Case Report and Review of the Literature

Clicks: 17
ID: 333328
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #153 of 247 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Purpose To describe a case report of upadacitinib interaction with warfarin, resulting in a supratherapeutic international normalized ratio (INR). Summary A 41-year-old female with a history of severe refractory atopic dermatitis was initiated on upadacitinib, a Janus kinase (JAK) inhibitor. She additionally had a history of mechanical mitral valve replacement for which she was maintained on warfarin with a target INR of 2.5-3.5. After nearly a week of concomitant upadacitinib 15 mg and warfarin, with no other changes in medications or food, her INR increased to 9.3, for which she was sent to the emergency department and received oral vitamin K. Her INR returned to baseline and upadacitinib was discontinued. Several weeks later, due to refractory atopic dermatitis symptoms, she took another two doses of upadacitinib and her INR increased to 4.7. She was instructed to take no further upadacitinib, her INR subsequently normalized with warfarin dose modification, and her atopic dermatitis therapy was changed. Conclusion Upadacitinib labeling does not include interaction with systemic anticoagulation nor increases in INR. The mechanism of this interaction remains to be elucidated, but an imbalance in pro-thrombotic and anti-thrombotic activity from various downstream cytokine inhibition may play a role. Clinicians should be aware of this potential paradoxical effect in patients on systemic anticoagulation who are initiating JAK inhibitors.
Reference Key
openalex_W7223178973 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lindsey Buscemi, Rishab Revankar, Bridget Bryer
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag350
URL
https://doi.org/10.1093/ajhp/zxag350
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.